Guaifenesin/hydrocodone/pseudoephedrine - Mission Pharmacal

Drug Profile

Guaifenesin/hydrocodone/pseudoephedrine - Mission Pharmacal

Alternative Names: Guaifenesin/hydrocodone bitartrate/pseudoephedrine hydrochloride - Mission Pharmacal; HycofenixTM

Latest Information Update: 04 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mission Pharmacal
  • Class Amines; Antitussives; Expectorants; Morphinans; Opioid analgesics
  • Mechanism of Action Alpha adrenergic receptor agonists; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cough; Nasal congestion

Most Recent Events

  • 28 Nov 2015 Mission has patent protection for Hycofenix™ in USA
  • 19 Nov 2015 Launched for Cough in USA (PO) before November 2015
  • 19 Nov 2015 Launched for Nasal congestion in USA (PO) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top